S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
NASDAQ:FLXN

Flexion Therapeutics (FLXN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$9.12
$9.12
50-Day Range
$9.12
$9.44
52-Week Range
$4.30
$13.66
Volume
N/A
Average Volume
1.18 million shs
Market Capitalization
$458.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FLXN stock logo

About Flexion Therapeutics Stock (NASDAQ:FLXN)

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

FLXN Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
VIRI Virios Therapeutics, Inc.
Spyre Therapeutics Inc SYRE
PFIZER INC's Net Worth
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
PCRX Pacira BioSciences, Inc.
Coherus BioSciences Inc. News
See More Headlines
Receive FLXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/12/2021
Today
4/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FLXN
Employees
257
Year Founded
2007

Profitability

Net Income
$-113,710,000.00
Net Margins
-100.32%
Pretax Margin
-100.32%

Debt

Sales & Book Value

Annual Sales
$85.55 million
Book Value
($0.34) per share

Miscellaneous

Free Float
45,727,000
Market Cap
$458.93 million
Optionable
Optionable
Beta
1.53

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Michael D. Clayman
    President, Chief Executive Officer & Director
  • Fred Driscoll
    Chief Financial Officer
  • William T. Andrews
    Chief Medical Officer
  • Carolyn Beaty Scimemi
    Chief Compliance Officer & Head-Legal Affairs
  • Christina WillwerthChristina Willwerth
    Chief Strategy Officer

FLXN Stock Analysis - Frequently Asked Questions

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) posted its earnings results on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.08. The specialty pharmaceutical company earned $24.59 million during the quarter, compared to analyst estimates of $24.61 million.

What is Mike Clayman, MD's approval rating as Flexion Therapeutics' CEO?

46 employees have rated Flexion Therapeutics Chief Executive Officer Mike Clayman, MD on Glassdoor.com. Mike Clayman, MD has an approval rating of 85% among the company's employees.

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

This page (NASDAQ:FLXN) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners